The supplement to the May/June 2008 issue of JWOCN (35:3S), Scientific and Clinical Abstracts from the 40th Annual Wound, Ostomy and Continence Nurses Annual Conference included two errors.
ORAL ABSTRACT #2104
End colostomy-related complications
The corrected author line is as follows:
Sungho Jo Sr., MD, PhD, Handong University Sunlin Hospital, Pohang, South Korea; Seungmi Park, RN, MSN, Departmnt of Nursing, Sunlin College, Pohang, South Korea; and Kyung Hee Park, CWOCN, Samsung Medical Center, WOC Nursing Education Program, Seoul, South Korea.
RESEARCH ABSTRACT #2437
The abstract text was incorrect. The heading and the correctly associated abstract are included below.
Comparison of the Kinetics of Papain-Urea Enzymatic Debridement
Mark W. Trumbore, PhD, [email protected] and Wayne Alden IV, [email protected], Collegium Pharmaceutical, Cumberland RI
Papain-Urea is an enzymatic debrider typically used when significant debridement is required. It works by digesting the proteinaceous components of necrotic tissue, resulting in a clean wound bed. Enzymatic debridement produces therapeutic benefits and is associated with reduced infection and lower risks of hospital re-admission. Papain-urea has been shown to be faster and more effective in debriding wounds and promoting healing than other enzymatic treatments. There are numerous papain-urea products on the market, some of which have been available for over 50 years. All of the products contain similar concentrations of papain and are frequently used interchangeably. Recently, a novel Papain-Urea Aerosol Foam formulation demonstrating robust enzymatic activity was introduced. In order to compare the kinetics of protein digestion of the Papain-Urea Aerosol Foam with that of the leading Papain-Urea Ointment, the activity of the papain-urea products was examined in an in vitro wound model. The model replicates a wound environment by presenting a fully hydrated substrate matrix containing embedded protein. The embedded protein is degraded by the papain to form a zone of clearance allowing measurement of activity as a function of time at 30, 60, and 90 minutes, 2 hours and 4 hours. The results indicate that the Papain-Urea Aerosol Foam formulation demonstrated the fastest rate of clearance and the greatest extent of clearance at 4 hours. While not comparing the clinical efficacy of the papain-urea debriders, the results of this study suggest that differences in enzymatic activity might influence clinical outcome.